| |
Cardiovascular disease accounts for 40% of all hospital revenue and 1 out of every 2.7 deaths in the United States. Over 500,000 Americans survive heart attacks every year and need to be diagnostically monitored. In the US alone, over 280,000 patients have various heart devices implanted. The US Department of Health and Human Services estimates that heart disease costs, including hospital expenses, home care, medications and lost earnings, exceed $400 billion. Experts estimate that 85% of cardiovascular disease could be prevented or halted by sufficiently early diagnosis.
According to the American Heart Association, a patient that survives the acute stage of a heart attack has a chance of illness and death that is 1.5-15 times higher than that of the general population.
|
|
Signalife's patented heart monitoring technology will allow physicians to monitor patients in an ambulatory setting, giving them access to vital life-improving and life-saving information.
Heart disease is the number one killer of women worldwide, yet it often goes undiagnosed or misdiagnosed. According to the CDC, more US women died of heart disease in 2003 than of cancer, lung disease, diabetes and Alzheimer's combined. Signalife’s Fidelity100 ECG will afford physicians the opportunity to diagnose heart disease in women earlier and more accurately.
|
|
